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Background: Non-adherence to antipsychotic medication is commonly found in schizophrenia and other psychotic
disorders, thus forming a major obstacle to long-term maintenance treatment and contributing to high relapse rates.
With limited evidence on the success of interventions in enhancing medication adherence, this controlled trial was
designed to test and evaluate the effectiveness of an adherence therapy (AT) for outpatients with schizophrenia
spectrum disorders, based on a motivational interviewing approach over a six-month follow-up period.
Methods: A single-blind, randomized controlled trial with a repeated-measures, two parallel groups design was
conducted in a random sample of 114 participants with schizophrenia spectrum disorders in one community
psychiatric nursing service. After pre-test, the participants were randomly assigned to either an eight-session
course of AT plus usual care or usual psychiatric care (n = 57 per group). The main outcomes, including medication
adherence, symptom severity, insight into treatment, hospitalization rate, and functioning, were measured at baseline
and immediately and six months post-intervention.
Results: A total of 110 participants completed this trial and thus the attrition rate was 3.5 %. Results of
repeated-measures analysis of variance followed by Helmert’s contrasts test indicated that the AT participants
reported significantly greater improvements in their insight into illness and/or treatment, psychosocial functioning,
symptom severity, number of re-hospitalizations, and medication adherence (F = 5.01 to 7.45, P = 0.007 to 0.030) over
six months follow-up, when compared with usual care.
Conclusions: Motivational interviewing-based AT for people with schizophrenia can be effective to reduce symptom
severity and re-hospitalizations, and improve medication adherence, functioning, and insight into illness and/or
treatment over a medium term (six months) period of follow-up. Further study on the effects of AT in people
with psychotic disorders in terms of diverse sociodemographic and illness characteristics, and a longer term
(for example, over 12 months) follow-up period is recommended.
Trial registration: The trial was registered at Clinicaltrials.gov (identifier: NCT01780116) on 6 July 2014.
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People with a diagnosis of schizophrenia spectrum dis-
orders, such as schizophrenia, schizophreniform, and
schizoaffective disorders, constitute about 60 to 70 % of
psychiatric patient populations served by community
mental health services [1]. The use of antipsychotic
medication in acute, chronic, and maintenance stages
of the illness for symptom reduction, improvements of
psychosocial functioning, and relapse prevention in
these psychotic patients is widely accepted. Neverthe-
less, systematic reviews on clinical trials have suggested
that levels of adherence to oral antipsychotics among
these patients were generally poor, ranging from 40 to
70 % [2,3]. Despite the advent of new (atypical) antipsy-
chotics with less side-effects, some adverse effects of
these novel drugs, such as tardive dyskinesia and obes-
ity, are highly intolerable and detrimental to patients.
While there has been increasing number of patients
using these atypical antipsychotics, it appears that little
progress has been made on increasing medication
adherence in patients with schizophrenia. Continuous ef-
forts are required for the design of innovative and effective
interventions, which can be evaluated in improving medi-
cation adherence and other patient outcomes among
patients with schizophrenia, thus reducing their rate of re-
lapse occurrence [4].
Among various factors such as long duration and
serious adverse effects of medication and lack of social
and family support [5,6], a lack of insight into the
illness and medication taking is one of the most im-
portant inhibiting factors influencing medication adher-
ence to antipsychotics and other treatments in patients
with schizophrenia spectrum disorders [7]. In addition,
acute and severe psychopathology (for example, suspi-
cions and delusional beliefs), and any delay in seeking
treatment during the early stages of schizophrenia, can
render it difficult for prompt and efficacious interventions
and understanding about the significance of medication
adherence, thus reducing the likelihood of their adherence
behaviors [6,8].
‘Adherence’, sometimes used interchangeably with
‘compliance’ in the literature, means that a patient
accepts the advice of healthcare professionals to take
medication according to a medical prescription. Indeed,
it also reflects the recognized needs for, and importance
of taking the prescribed medication from the patient’s per-
spective [2,9,10]. Systematic reviews on recent clinical
trials indicate that current multi-faceted and complex
psychosocial interventions for people with schizophre-
nia can only demonstrate modest and inconsistent ef-
fects on improving patients’ treatment adherence and/
or other psychosocial outcomes over a short-term
follow-up period (for example, six months) [2,3,11]. For
instance, psycho-educational programs for people withpsychotic disorders, which aimed to enhance know-
ledge about mental illness and its medications and/or
treatments, were found to be non-significant in pro-
moting positive attitudinal and behavioral changes in
these patients’ treatment adherence [1,6].
Neither psycho-educational interventions nor behav-
ioral modifications have been found to have a significant
effect on medication adherence. One recent controlled
trial reported that psycho-educational or behavioral
management programs for people experiencing an
acute episode of psychosis could significantly reduce
their symptom severity, yet no significant effect was
found on the patients’ adherence rate, insight to treat-
ments, nor functioning [12]. Researchers are unable to
confirm or explain the mechanisms of change induced by
strategies in improving medication adherence used, but in
order to enhance medication adherence, most recommend
that important factors such as patients’ knowledge, atti-
tude, and perceived (or experienced) stigma towards the
illness and its treatment, and therapeutic alliance with
professionals should be considered [13].
In addition, recent studies have suggested that pa-
tients’ adherence to medication could be improved by
assisting them in understanding and accepting their
illness and its treatment, and in coping with those prob-
lems concerning the medication used and its adverse ef-
fects [5-7]. Schizophrenia sufferers with a better insight
into their illness can demonstrate a better treatment
adherence; whereas, a greater perceived susceptibility to
re-hospitalization is associated with an increased level of
adherence to treatment [3,14]. Motivational interviewing
has recently found to be particularly useful for people
with addictions or high resistance or reluctance to treat-
ments who are ambivalent to changing their behaviors
[11]. This therapeutic approach to behavioral interven-
tion has recently been adopted to enhance adherence to
medication in schizophrenia, with positive preliminary
evidence on reducing patients’ psychotic symptoms and
relapse rates [8,11]. These positive findings suggest a
need for further scrutinizing of the effects of this motiv-
ational and self-empowered (both cognitive and emotional
focused) approach in different patient outcomes in terms
of not only symptom severity and relapse from the illness,
but also patients’ medication adherence, insight into ill-
ness and/or treatment, and psychosocial functioning in
those with poor adherence to antipsychotic medication.
Recent clinical practice guidelines, such as the 2014
National Institute of Health and Care Excellence guide-
lines, recommend an assessment of individual patients’
motivation and potential barriers to adherence to their
prescribed medication and treatment regimen prior to
any medical treatment or psychosocial intervention for
people with schizophrenia [15]. Nevertheless, the most
recent systematic reviews on compliance therapy for
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approaches to medication compliance (that is, merely
following what has been prescribed) could not fully
support their benefits on patient functioning and re-
lapse prevention, as well as the generalization of their
findings across cultures [3,11].
Based on the preliminary evidence on adherence therapy
(AT), an innovative model of a 12-session course of AT
for people with schizophrenia was developed and modi-
fied from Kemp et al. [8]. The AT mainly involved a com-
bination of techniques in motivational interviewing,
cognitive behavioral therapy, and psycho-education. It
was tested in the United Kingdom and Thailand, with
positive results on reducing symptom severity and relapse
rates, and enhancing levels of medication adherence in
schizophrenia [5,15]. Gray et al. [11] modified this AT
program into a brief (eight session) course based mainly
on motivational interviewing, coping, and problem-
solving skills. The modified program conducted in a
few European countries demonstrated significant im-
provements in psychotic symptoms and relapse preven-
tion in schizophrenia over a six-month follow-up
period, but not in their insight into illness, functioning,
and quality of life.
Therefore, this randomized controlled trial was de-
signed to test the effects of a modified AT program for
Chinese outpatients with schizophrenia spectrum dis-
orders (together with principles of cognitive behavioral
therapy), as recommended by Gray et al. [16]. We
hypothesized that that the participants who received
AT would demonstrate significantly greater improve-
ments in symptom severity at immediately and six
months after completion of the intervention, compared
with treatment as usual (TAU). In addition, we also
hypothesized that the AT participants would show greater
improvements in secondary outcomes, including medica-
tion adherence rate, re-hospitalization rate, psychosocial
functioning, and insight into illness and/or treatment, over
the six-month follow-up period.
Methods
This was a single-blind, randomized controlled trial of
a motivational interviewing-based medication AT pro-
gram for patients with schizophrenia spectrum disor-
ders, using a repeated-measures, parallel groups (AT
versus TAU) design. Fig. 1 shows the flow diagram of
the trial procedure according to the revised version of
the Consolidated Standards of Reporting Trials state-
ment [17]. Ethical approvals of this trial were obtained
from the Human Subjects Research Ethics Committee
of The Hong Kong Polytechnic University (reference
number: HSEARS20120101004), and the community
nursing service under study. Written informed consent
was obtained from individual participants after clearexplanation of the purpose and procedure of the study
by the first author.
Participants and recruitment
The study was conducted between December 2012 and
January 2014 at one Community Psychiatric Nursing
Service (CPNS) in the New Territories of Hong Kong,
which served about 20,000 patients discharged from two
regional mental hospitals. There were more than 2,500
potential participants (12.5 % of the total patient popula-
tion) primarily diagnosed with schizophrenia spectrum
disorders such as schizophrenia, schizoaffective disorder,
and schizophreniform disorder. A research assistant
(RA) checked the patient records in the CPNS and
found that 850 patients met the study criteria. These
patients were assessed by their attending psychiatrist to
confirm their mental competence for participation in the
study (that is, being able to understand and complete
the study questionnaires). A list of eligible participants
was developed in alphabetical order of their surnames. A
set of computer-generated random numbers provided by
an independent statistician, who was blind to the patient
list and not involved in other parts of the study, was
used for participant selection from the list of eligible
patients. Of 174 eligible participants approached indi-
vidually by the RA, 114 participants (65.5 %) agreed to
participate after providing their written consent.
Participants were included if they were: (a) aged be-
tween 18 and 60 years, Hong Kong residents speaking in
Mandarin or Cantonese; (b) having a primary diagnosis
of schizophrenia spectrum disorders in the past five
years, according to the criteria of the revised fourth
edition of Diagnostic and Statistical Manual for Mental
Disorders (DSM-IV-TR) [18]; and (c) had poor adherence
to medication as indicated by a Drug Attitude Inventory
score of 11 or below [5], and/or recent history of non-
adherence to antipsychotic medication. Non-adherence to
medication was defined as a recent history of cessation of
oral antipsychotics associated with psychiatric admission
or for more than one month at a time [3,11], or missed an
average of more than two doses per week in the past three
months [3,5] according to the assessment by their attend-
ing psychiatrist or community psychiatric nurse and/or
self-reported by patients themselves. Exclusion criteria of
this study were those patients who had: (a) regular depot
or intramuscular injection(s) only; (b) co-morbidities of
learning disability, organic brain disease, and/or cognitive
impairments; (c) previous participation in any medication
management program; and/or (e) hostel (or halfway
house) residents supervised by mental health workers to
take their medications.
Those patients who were randomly selected (n = 114)
and completed the baseline measures (T0) were randomly
assigned by the RA into one of the two study arms,
Fig. 1 A flow diagram of the procedure of this clinical trial. After confirming eligibility and written consent, 114 patients with schizophrenia spectrum
disorders were randomly selected from a patient list and randomly assigned into one of the two study arms (motivational interviewing-based
adherence therapy or treatment as usual) after completing the baseline measurements. Fifty-four participants in the adherence therapy and
56 in the treatment-as-usual group completed one to three post-tests over a six-month follow-up period, and finally included in the data analyses.
Only four participants dropped out during the study period. AT, Adherence Therapy; CPNS, Community Psychiatric Nursing Service; ITAQ, Insight and
Treatment Attitude Questionnaire; PANSS, Positive and Negative Syndrome Scale; SLOF, Specific Level of Functioning Scale; TAU, Treatment as usual
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labeled card (1 = AT, 2 = TAU) from an opaque envelope.
Those 57 participants in the AT were also assigned to one
of six trained community psychiatric nurses according to
their sequence of date of home visit. The lists of partici-
pants and their intervention assignment were concealed
to the researchers, assessors, and CPNS staff until comple-
tion of all post-tests.
Sample size calculation
The sample size calculation was based on the average ef-
fects size on symptom severity (Positive and NegativeSyndrome Scale; 0.48 to 0.54) and level of medication
adherence (Positive and Negative Syndrome Scale; 0.46 to
0.52) at immediately post-intervention in four clinical
trials of AT [8,16] or psycho-education programs with
medication management as core components in schizo-
phrenia [1,19]. With the level of statistical significance set
at P = 0.05 (two-sided) and a study power of 80 %, the
sample size was 47 per group to detect an average effect
size (Cohen’s d) of 0.50 on the above two outcomes, using
G*Power 3.1 for Windows [20], taking into account an at-
trition rate of 20 % [10,19]. Hence, 114 participants were
randomly selected (n = 57 in each group).
Table 1 An outline of adherence therapy
Phase/Session Interventions Main assignments
Phase 1 (2 sessions) Purposes: Reviewing antipsychotic medication use and the impacts
of psychotic symptoms on medication (and treatment)
adherence, the desired and unwanted effects of medication,
neuroleptic side effects, and attitude and satisfaction with
medication taking.
(1) To help participants review their past and present states of
taking antipsychotics; and
(2) To assess knowledge, attitude, and barriers to medication
adherence, and plan for problem-solving and improving
adherence behaviour using a standard assessment form.
Participants identify the present beliefs and concerns, benefits
and barriers related to medication and rated the level of distress
(1 to 10) attached to each side effect.
Examining and addressing beliefs and concerns towards
adherence, and plan for problem-solving.
Families are asked for their opinions and attitudes on their
relative’s attitude towards medication taking.
Homework assignment: Weekly record of adherent
behaviour and reasons for adherence or non-adherence.
Participants are asked to do homework by recording weekly
medication adherent behaviors, and both they and nurse
therapist keep a record of documentation.
The nurse therapist makes an attempt to link medication cessation
with relapse. Negative treatment experiences and high level of
distress regarding side effects are acknowledged and discussed.
Denial of need for treatment is met with gentle enquiry into the
ensuring social consequences and lifestyle disruptions.
Phase 2 (3 sessions) Purposes: Revisiting and revising previous goals or add new ones,
and their actions.
(1) To educate about mental illness and the treatment and care
required;
(2) To review the goals, actions, and adherence records of the
last two weeks; and
Recognizing factors that may lead to poor adherence,
and developing coping strategies to reduce urges for
non-adherence
(3) To identify barriers to medication adherence and to develop
coping strategies, new goals and actions.
Homework assignment:
Participants’ confusion between symptoms and side effects, and
misconceptions of antipsychotic medication is further clarified.
Practicing new actions for maintaining or enhancing
adherence. Weekly record of adherent behaviors and
reasons for adherence/non-adherence to medication.
The natural tendency to stop medication whenever the participants
feel well is to be discussed, and their meanings attached to
medication are explored, that is, an identity as a ‘sick person’.
Participants are asked to weigh up the benefits and drawbacks
of treatment, and the nurse therapist will focus on the benefits,
especially when they emerge spontaneously.
Symptoms reported by the participants are fed back as their
needs (‘symptoms’) for treatment.
Phase 3 (3 sessions) Purposes: Evaluation of the progress of medication adherence with
each participant and his/her change in beliefs/insight into
illness and treatment during session 6.(1) To rationalize participants’ beliefs and concerns and to
prevent relapse;
(2) To manage social stigma and enhance social support.
Participants are facilitated and encouraged to identify the
characteristics of prodromal symptoms and analyze the
importance of early intervention to prevent a full-blown episode.
Making future plan with participants to continue self-
monitoring of medication adherence and its contractual
agreement; and clarifications of means of support from
the CPNS, family and services.
In sessions 7 and 8, the nurse therapist use normalizing rationale to
deal with stigma towards the illness and/or medication; suggest an
analogy with physical illness requiring maintenance treatment; and
highlight illness prevalence with examples of ex-patients who have
been successful in coping with similar difficulties as theirs.
Homework assignment:
Weekly record of medication behaviors and reasons for
adherence and non-adherence.
Participants reframe medication use by participants as a freely
chosen strategy to enhance control of quality of life and use
metaphors of medication as an ‘insurance policy’ for staying well.
Risk assessment for relapse prevention and a list of risk
factors identified and recorded on a standard form.
A future plan and contractual agreement are made to continue
monitoring of medication adherence and means of support
from the CPNS, family, and other mental health care services are
clarified.
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Motivational interviewing-based AT in this study was
based on Gray et al.’s [11] eight-session AT using the
motivational interviewing technique (and principles of
cognitive behavioral therapy). Motivational interviewing
techniques involving cognitive, motivational, insight-
inducing, and behavioral training are viewed as particu-
larly useful for people with addictions and/or strong
resistance and ambivalence to treatment regimen and
adherence [5]. Principles of motivational interviewing
were adopted to facilitate a non-confrontational ap-
proach to the participants, including: (a) expression of
empathy; (b) creating discrepancy or challenges with
false beliefs or myths; (c) avoiding arguments and anger;
(d) rolling with resistance; and (e) supporting self-
efficacy and self-empowerment [8]. Whilst it was consid-
erably more difficult to discuss issues in motivation and
attitudes towards treatments with participants express-
ing severe psychotic symptoms (such as delusion, apathy,
and anhedonia), motivational interviewing combined
with knowledge acquisition and training in problem-
solving and coping skills, could be useful for focusing on
specific impacts of illness behaviors on these patients,
and provide them with opportunities to engage and
discuss their ambivalent attitudes towards their illness
behaviors, treatments, and possible consequences of non-
adherence [11,12].
The AT (a four-month program) consisted of three
phases in which eight two-hour sessions were held at
participants’ homes every two weeks by one of the six
trained community psychiatric nurses. This AT was val-
idated and agreed by two psychiatrists, two community
psychiatric nurses, and two outpatients with schizo-
phrenia to ensure feasibility and cultural appropriate-
ness with the local community mental health services;
only a few re-arrangements of the topics were made in
the third, fourth, and sixth session (perceived barriers
to medication adherence; social stigma and family sup-
port within a cultural context; and impacts of stigma
towards medication on patients’ behaviors and coping,
respectively) [21,22]. An outline of the AT program is
presented in Table 1. The first phase of AT (two ses-
sions) aimed to engage participants in addressing their
needs for, and concerns with medication adherence,
facilitating goal and action setting for changes in medi-
cation adherence. The second phase (three sessions)
focused on education about the mental illness and its
treatment, and then explored patients’ strengths and
barriers to adherence, assisting them in recognizing
social stigma and family support, and developing cop-
ing strategies in medication management over months.
The third phase (three sessions) aimed to rationalize
patients’ beliefs and concerns, manage their perceived
or experienced social stigma, and enhance family andsocial support networks, thus improving relapse pre-
vention and integration into the community.
The AT was carried out by six trained community psy-
chiatric nurses during their home visit for the assigned
participants; each of them conducted this therapy for
between nine and 10 participants who were randomly
selected from between 40 and 45 patients in their case-
loads. All participants were asked not to tell their
psychiatrists and other staff in CPNS about their partici-
pation in the study. While only these six community
nurses implemented AT to the assigned patients, other
community nurses in the CPNS were concealed to the
participant assignments to the interventions. These
nurse therapists had received two full-days training by
the research team based on both the AT instructor pro-
gram developed by Gray et al. [11] and a psycho-
education program for Chinese patients with schizo-
phrenia [1,21]. The trained nurses were provided with
supervised practices on AT for at least three outpatients
with schizophrenia until the supervisors (the first and
second authors) agreed and confirmed the consistency
and competency of their implementation of the treat-
ment protocol (over 90 % of items rated as ‘Fully compe-
tent’), using a validated competency scale of AT [16].
During the therapy, three sessions were randomly se-
lected for each nurse therapist, audio-taped (with the
nurses’ and participants’ prior consents) and assessed by
two raters (researchers) to monitor the treatment fidelity
using the same competency scale. The fidelity of treat-
ment implementation (rated as ‘Fully competent’) ranged
between 90 % and 98 % on the items of the scale (me-
dian = 94 %).
The participants in the TAU group received routine
community mental health services offered by the CPNS
under study and its affiliated outpatient clinic. TAU con-
sisted of psychiatric consultations at the outpatient
clinic, home visits by a community psychiatric nurse
every four to six weeks with mental health assessments,
a brief education on mental illness and its treatments,
and referrals to mental healthcare services by a psych-
iatrist and to social welfare services by a medical social
worker.Measures
Participants were asked to complete four outcome mea-
sures at recruitment (T0) and immediately (T1) and six
months (T2) post-intervention by the RA who was
blind to their intervention assignment. The primary
outcome was symptom severity measured with the
Positive and Negative Syndrome Scale (PANSS). The
secondary outcome measures included the Insight and
Treatment Attitude Questionnaire (ITAQ), Adherence
Rating Scale (ARS), frequency and length (days) of
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Functioning Scale (SLOF).
Positive and Negative Syndrome Scale
The 30-item PANSS developed by Kay et al. [23] assessed
the severity of psychotic symptoms in terms of three
subscales, including positive symptoms (hallucinations,
delusional beliefs, and thought disorganization), nega-
tive symptoms (blunted affect, social withdrawal, and
lack of spontaneity), and general psychopathology (man-
nerisms, abnormal posture, and unusual thought con-
tents). Its items were scored on an eight-point Likert
scale (from 1-‘Absent’ to 7-‘Extremely’). The scale
demonstrated good concurrent validity with the Brief
Psychiatric Rating Scale (Pearson’s r = 0.85 to 0.90),
test-retest reliability (intra-class correlation = 0.85 to
0.90) and internal consistency (Cronbach’s α = 0.88 to
0.91) in people with psychotic disorders [24].
Adherence Rating Scale
The ARS developed by Staring et al. [13], which was
user-friendly and valid and overcame the constraints
and difficulties in pill counts, urine tests, and invasive
and expensive serum assays [8], measured the level of
medication adherence in this study. It was a single-item
rated on a five-point scale (1-‘Total non-adherence’,
2-‘Poor adherence’, 3-‘Inadequate adherence’, 4-‘Fair
adherence, and 5-‘Good adherence’) by the RA and
participants attending a psychiatrist or outpatient clinic
nurse (who were blind to their intervention assign-
ment) independently, by asking patients and/or their
family members about their drug-taking behaviors and
conducting an examination of the patient’s outpatient
and CPNS records. Excellent inter-rater reliability (95 to
100 % agreement) and content validity were demonstrated
in Coldhan et al. [25], a study in American patients with
psychotic disorders. If any difference was found on the
ratings between the two raters, discussion and final con-
sensus was made by the two raters, with consultation to
the patients’ case managers in the CPNS.
Insight and Treatment Attitude Questionnaire
The 11-item ITAQ assessed patients’ insight into their
mental illness and needs for treatments [26]. Items
were rated on a 3-point Likert scale (0-‘No insight’;
1-‘Partial insight’, and 2-‘Good insight’); the higher the
total score, the better the patient’s insight into the
illness and its treatments. The Chinese version used in
this study indicated satisfactory internal consistency
(Cronbach’s α = 0.82), inter-rater reliability (intra-class
correlation = 0.82), and concurrent validity with symp-
tom severity and psychopathology measures (Pearson’s
r = 0.56 and 0.60, respectively, both P values = 0.001) in
Chinese patients with schizophrenia [21,27].Specific level of functioning scale
The 43-item SLOF assessed three functional domains
of patients with schizophrenia, including self-maintenance
and self-care (12 items), social functioning (14 items),
and community living skills (17 items) [28]. Its items
were rated on a five-point Likert scale (from 1-‘Totally
dependent’ to 5-‘Highly self-sufficient’). The Chinese
version used in this study demonstrated satisfactory
content validity, test-retest reliability (intra-class correl-
ation = 0.80), and internal consistency (Cronbach’s α =
0.88 to 0.96) in Chinese patients with psychotic disor-
ders [29,30].
Re-hospitalization rate
Number and length (days) of psychiatric hospitalizations
over the past four months were reported by participants
at pretest and two post-tests, and verified with their clin-
ical records in the CPNS. In addition, the nature of each
admission (voluntary or compulsory) was recorded to
identify patients’ willingness and involvement in psychi-
atric treatments.
Procedure
During home visits, participants completed all of the
above-mentioned outcome measures at recruitment
(T0) and immediately (T1) and six months (T2) after
their completion of the interventions. Participants also
complete a sociodemographic data sheet at recruit-
ment, which included patient’s gender, age, education
level, monthly household income, and duration of men-
tal illness. Their re-hospitalizations and duration of
illness were examined and confirmed with the CPNS
records (that is, the electronic patient records system).
Data analysis
All quantitative data in the AT and TAU group were
numerically coded and analyzed on an intention-to-treat
basis, using SPSS for Windows, version 20.0 (IBM Corpor-
ation, New York, USA). Goodness of fit chi-square test
(for categorical data) and independent sample t test (for
interval or ratio data) were adopted to test the heterogen-
eity of two groups in terms of their sociodemographic
characteristics and mean values of the outcome measures
at baseline. Data on AT participants’ attendance, dropouts,
receiving other psychosocial interventions, and types and
doses of psychotropic medications used over the study
period were analyzed. Repeated-measures analysis of
variance (ANOVA) test was performed for each of the
outcome variables (ITAQ, PANSS, SLOF, ARS, and num-
ber and length of re-hospitalizations) to determine the
treatment effects in terms of within-group, between-
groups, and interactive group-by-time modes [31]. Very
few missing data were found and thus were replaced by
their group mean values [32]. For those outcomes with
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mert’s contrasts tests were performed to test any signifi-
cant differences on their mean values between groups at
each of the two post-tests. The level of statistical signifi-
cance was set at 5 %.
Results
Sample characteristics
A total of 114 participants completed the questionnaires
at baseline. Of them, 110 were included in the final data
analysis (attrition rate of 3.5 %); three failed to attend
more than four AT sessions and one in the TAU group
was lost to follow-up. Average attendance to AT sessions











Employment status Employed (full-time)
Employed (part-time)
Unemployed
Others (for example, an intermit
Education level Primary school
Secondary school
University/college





Treatment setting Outpatient department
(other than CPNS) Day hospital/center
Others





Others (for example, hostel or lo
AT: Motivational-interviewing-based Adherence Therapy, TAU: Treatment as usualSociodemographic (and clinical) characteristics of the
114 participants are summarized in Table 2. About half
of them were male (50.9 % and 52.6 % in AT and TAU,
respectively), two thirds were diagnosed as schizophrenic
(61.4 % and 63.2 %, respectively), and two thirds were
recently employed in full- or part-time work (both
63.2 %). The participants had a mean age of 28 to
29 years, mainly ranging from 18 to 49 years (>94 %).
Most of them had obtained secondary school or univer-
sity education (>85 %) and had less than a two-year
duration of mental illness (84.2 % and 90.7 %, respect-
ively). All were receiving psychiatric outpatient and/or
daytime hospital services. About two thirds were living
with their families (66.7 % and 64.9 %, respectively) andaseline (N = 114)
AT (n = 57) TAU (n = 57) χ 2, P
f (%) f (%)
29 (50.88) 30 (52.63) 1.30, 0.23
28 (49.12) 27 (47.37)
(29.21, 9.64) (28.13, 8.96)
18 (31.58) 17 (29.82) 1.68, 0.14
27 (47.37) 25 (43.86)
9 (15.79) 12 (21.05)
3 (5.26) 3 (5.26)
35 (61.40) 36 (63.16) 1.08, 0.28
22 (38.60) 21 (36.84)
26 (45.61) 25 (43.86) 1.29, 0.21
10 (17.54) 11 (19.30)
14 (24.55) 16 (28.07)
tent job) 5 (7.5) 8 (11.9)
8 (14.04) 9 (15.79) 1.53, 0.12
41 (71.93) 40 (70.17)
8 (14.04) 8 (14.04)
(19.91, 11.88) (20.42, 10.38)
20 (35.09) 19 (33.33) 1.33, 0.20
18 (31.58) 18 (31.58)
9 (15.79) 9 (15.79)
8 (11.9) 11 (19.30)
57 (100.00) 57 (100.00) 1.41, 0.19
9 (15.79) 8 (14.04)
10 (17.54) 12 (21.05)
12 (21.11) 11 (19.30) 1.01, 0.31
38 (66.67) 37 (64.91)
7 (12.28) 9 (15.79)
21 (36.84) 20 (35.09) 1.83, 0.10
25 (43.86) 23 (40.35)
ng-stay care homes) 11 (19.30) 14 (24.56)
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(80.7 % and 75.4 %, respectively). There were no signifi-
cant differences on all of these sociodemographic char-
acteristics between the AT and TAU group, using the
chi-square test (P ≧0.12).Results of outcome measures at baseline
The results of all outcome measures (ITAQ, PANSS,
SLOF, ARS, and re-hospitalization rates) at baseline are
summarized in Table 3. There were no significant dif-
ferences on their mean scores between the AT and
TAU (P ≧0.10). The majority (87.9 % in AT and 85.9 %
in TAU) were deemed totally non-adherent or poorly
to inadequately adherent to medication in both the AT
and TAU groups (mean score of 1.48 and 1.39; SD =
0.98 and 1.01, respectively) at baseline. The average
number of re-hospitalizations over the past four
months were 1.41 (SD = 0.98) and 1.50 (SD = 0.92) in
the AT and TAU group, respectively; in which about
65 % were ‘compulsory’ admissions (67 % in AT and




ITAQ (0–22)a 9.12 6.14
PANSS
Total score (30–210)a 80.19 11.10
Positive symptoms (7–49)a 15.39 5.12
Negative symptoms (7–49)a 16.31 5.87
General psychopathology (16–112)a 48.49 9.12
SLOF
Total score (43–215)a 140.01 18.22
Self-maintenance(12–60)a 42.11 5.52
Social functioning (14–70)a 42.00 5.88
Community living skills (17–85)a 55.90 8.01
Adherence rating scale (1–5)a 1.48 0.98
Total non-adherence (f, %) (22, 38.80) (20, 35.0
Poor to inadequate adherence (f, %) (28, 49.12) (29, 50.8




DAI (0–22)a 8.82 3.03
AT: Adherence therapy, DAI: Drug Attitude Inventory, ITAQ: Insight and Treatment A
Specific Levels of Functioning Scale, TAU: Treatment as usual
aPossible range of score in each measure in the parentheses. bAverage number of r
cDuration of psychiatric readmissions at each time point in terms of average numbeTreatment effects of adherence therapy
The mean scores (and SD) of the outcome measures at
pre-test and post-tests in both AT and TAU are shown in
Table 4. The results of repeated-measures ANOVA tests
indicated the AT group had significant greater improve-
ments over time (group × time interactions) than the TAU
group on the participants’ ITAQ, PANSS, SLOF, ARS, and
average number of re-hospitalizations. As indicated in
Table 4, the interaction (group × time) effects included: re-
ductions in the AT participants’ symptom severities
(PANSS score, F(1,109) = 7.32, P = 0.008; positive symp-
toms score, F(1,109) = 7.28, P = 0.008; negative symptoms
score, F(1,109) = 7.81, P = 0.006), with large effect sizes
of 0.70 to 0.75; reductions in average number of re-
hospitalizations (F(1,109) = 5.01, P = 0.03), with a mod-
erate effect size of 0.48; improvements in their insight
into illness and/or treatment (ITAQ score, F(1,109) =
6.58, P = 0.021), with a moderate effect size of 0.51; and
improvements in functioning (SLOF score, F(1,109) =
6.89, P = 0.014), with a large effect size of 0.68. In addition,
the medication adherence of the AT group showed a sig-





9.33 3.31 1.52 0.20








1.39 1.01 1.92 0.12
9) χ2 = 1.48 0.13
8)
)
1.50 0.92 1.83 0.12
10.01 4.02 2.33 0.10
9.01 3.71 1.51 0.13
ttitude Questionnaire, PANSS: Positive and Negative Syndrome Scale, SLOF:
eadmissions to a psychiatric hospital or inpatient unit in the past four months.
r of days of hospital stay over the past four months
Table 4 Results of repeated-measures ANOVA (group × time) tests for outcome measures at pre- and post-tests (N = 110)
AT (n = 54) TAU (n = 56)
T0 T1 T2 T0 T1 T2 Effect size
Instrument Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Fc, P
ITAQ 9.12 6.14 11.13 6.89 13.88 6.80 9.33 3.31 9.89 5.81 9.79 6.21 6.58, 0.021 0.51
PANSS 80.19 11.10 74.01 15.10 68.12 14.81 81.13 12.01 81.18 15.23 83.45 14.13 7.32, 0.008 0.71
Positive Symptoms 18.02 4.89 16.13 4.54 14.65 3.98 18.21 4.12 18.23 4.51 18.98 5.86 7.28, 0.008 0.70
Negative Symptoms 20.68 5.01 18.34 5.62 16.71 5.81 20.82 5.76 20.96 5.98 21.38 6.12 7.81, 0.006 0.75
SLOF 140.01 18.22 150.80 22.38 168.12 28.10 138.34 17.18 138.11 20.88 145.12 34.20 6.89, 0.014 0.68
ARS 1.48 0.98 2.12 1.08 3.08 1.24 1.39 1.01 1.45 1.00 1.48 1.01 7.45, 0.007 0.72
Re-hospitalization
Numbera 1.41 0.98 1.31 0.92 1.18 1.10 1.50 0.92 1.38 1.09 1.51 0.99 5.01, 0.030 0.48
Durationb 9.12 2.98 8.81 5.11 8.18 4.02 10.01 4.02 10.05 8.11 9.01 8.85 3.68, 0.090 0.26
AT: Adherence Therapy, ARS: Adherence Rating Scale; possible score range 1 to 5, with higher scores indicating better adherence to medication, ITAQ: Insight and
Treatment Attitudes Questionnaire; possible score range from 0 to 22, with higher scores indicating better insight, PANSS: Positive and Negative Syndrome Scale;
possible score range from 30 to 210, with higher scores indicating greater severity of symptoms; the possible scores of Positive and Negative Symptoms subscales
range from 7 to 49, SLOF: Specific Levels of Functioning scale; possible score range from 43 to 215, with higher scores indicating higher level of psychosocial and
self-care functioning, TAU: Treatment as usual, T0: Baseline measure at recruitment, T1: First post-test at immediately after completion of the interventions, T2:
Second post-test at six months after interventions
a Average number of readmissions to a psychiatric hospital or inpatient unit over the past four months, b Duration of readmissions to a psychiatric hospital or
inpatient unit in terms of average number of days of hospital stay over four months. c F values (group × time) for repeated-measures ANOVA test, df = 1,109
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when compared with the TAU group.
Results of Helmert’s contrasts test indicated that the
AT participants had significantly greater improvements
than those in the TAU group on the following patient
outcomes at post-tests:
1. Insight into illness and/or treatment significantly
increased at both T1 and T2 (mean difference
= 1.24 and 4.09, standard error [SE] = 1.10 and 0.60,
respectively);
2. Symptom severity (PANSS overall scale, Positive
Symptoms and Negative Symptoms) significantly
decreased at both T1 (mean difference = 7.17, 2.1,
and 4.33, SE = 0.23, 0.05, and 0.92, respectively) and
T2 (mean difference = 15.33, 2.62, and 4.67, SE = 0.61,
0.30, and 0.0.31, respectively);
3. Level of functioning significantly increased at both
T1 and T2 (mean difference = 12.69 and 23.00, SE
= 2.00 and 5.88, respectively);
4. Medication adherence rate significantly increased at
both T1 and T2 (mean difference = 0.55 and 1.60,
SE = 0.09 and 0.22, respectively); and
5. Number of re-hospitalizations significantly reduced
at T2 only (mean difference = 0.33, SE = 0.11);
whereas in TAU, it slightly increased across post-tests
(from 1.50 at T0 to 1.51 at T2).
Nevertheless, the results also showed that the types
and doses of psychotropic medication, nature of admis-
sion (voluntary or compulsory) and types and frequencyof participation in other psychosocial interventions did
not differ significantly between the two groups from T0
to T2 (using repeated-measures ANOVA or Kruskal
Wallis test, P >0.25). In addition, there were not any sig-
nificant differences on all mean outcome scores between
six AT subgroups in terms of the nurse therapists at pre-
and post-tests (using Kruskal Wallis test, P >0.10).
Discussion
This was one of very few clinical trials of AT based on
motivational interviewing and cognitive behavioral
techniques that was currently available, and found to
be successful (effective) in improving adherence to
antipsychotic medication among patients with schizo-
phrenia and its spectrum disorders. The results sup-
ported the study hypotheses that the participants who
received AT could demonstrate significantly greater im-
provements over a six-month follow-up period in their
primary outcome (mental state (symptom severity)) and
other secondary outcomes, including insight into ill-
ness, functioning, and number of re-hospitalizations, as
well as their adherence to medication. In addition, large
effects of AT (effect sizes of 0.68 to 0.72) were demon-
strated on improving a wide variety of patient out-
comes over the medium term (six months) duration of
follow-up.
The success in this AT is particularly important to
these group of psychotic patients who often have a poor
adherence to treatment and a high relapse rate (50 to
70 %) within the first five years of the illness [33], thus
having high risks of its recurrence, a long course, and
Chien et al. Trials  (2015) 16:270 Page 11 of 14poor prognosis [9]. It is also noteworthy that this motiv-
ational interviewing-based AT can improve not only the
positive symptoms (such as hallucinations and delusions)
that can often be reduced effectively by good adherence to
medication [13,16,34], but also those treatment-resistive
negative symptoms, for example, amotivation, anhedonia,
and social withdrawal. This result might be due to the
effects of the motivational interviewing technique, in which
the participants were facilitated to non-judgmentally and
freely explore and resolve ambivalence on their attitudes
and behaviors regarding the illness, its treatment, and
related life situations, and to engage them with an en-
hanced intrinsic motivation to change their treatment- and
health-related behaviors, such as medication adherence,
self-care, and help-seeking [35]. Other strategies in motiv-
ational interviewing, such as showing genuine empathy,
acceptance, and envisioning for a better future, could also
be helpful in energizing and fostering better initiatives,
therapeutic growth, and changes in negative symptoms
and passivity in this patient population [13,16].
These findings provide evidence that this AT, modified
from Kemp et al. and Gray et al. in Western culture
[8,11], can be a promising intervention across cultures for
enhancing positive attitudes and adherence towards anti-
psychotic medication, and in reducing psychotic symp-
toms in Chinese people with schizophrenia spectrum
disorders. While recent controlled trials on AT showed
inconsistent or non-significant results in European coun-
tries [5,8,12], the AT used in this study showed significant
effects on a variety of patient outcomes, including not only
positive symptoms and number of re-hospitalizations, but
also those variables often found non-significant in other
studies, such as negative symptoms, functioning, and
insight into illness and/or treatment [12]. With much
more positive findings than other studies of medication
adherence or management programs, AT has already over-
come several limitations and revealed a few key elements
of an effective psychosocial intervention. First, one fre-
quently reported limitation was the difficulty in recruiting
non-adherent patients, where the researchers concluded
that the insignificant results were, in part, due to the ceil-
ing effect on levels of adherence at baseline provided by
those with already good adherence to medication [12,16].
Noting such an effect, participants in this study were only
included if they were deemed non-adherent or poorly
adherent (ARS mean score of about 1.5 out of 4.0) before
the interventions.
Second, several studies reported an oversight of the
impact of clinicians’ characteristics and relationship
with patients in the effectiveness of psychosocial inter-
ventions, recommending that further studies utilize
patient-centered healthcare workers that have already
been part of the patient’s clinical team [9,16]. The AT was
administered by the participants’ attending communitypsychiatric nurse during home visits. This AT also
emphasized participant involvement during the later
phases of the intervention, enhancing the sense and
feelings of control and self-efficacy in self-regulation
and management of the illness and its treatment (and
medication), as suggested in other studies as predictive
factors of effective psychosocial interventions for people
with schizophrenia [22,36].
This study was also one of very few controlled trials to
date of AT conducted in Chinese or Asian populations.
When compared with other ATs or other interventional
studies in Western countries, much higher treatment
adherence and lower attrition rates were found in this
study, similar to several studies involving Chinese
patients [19,21,27]. Such increased adherence and/or
retention rates of patients with schizophrenia and other
severe mental illnesses may be related to culturally
defined perceptions of a strong relationship between
patients themselves and their healthcare providers and
much better patient compliance with study or treat-
ment protocols [37].
While there are arguments on whether patients’ en-
hanced insight into illness and/or treatment and adher-
ence behaviors are mediating factors rather than outcome
measures of AT [38,39], the AT tested herein can pro-
duce positive effects on not only patients’ attitude and
behavior regarding medication adherence, but also their
mental state and functioning. These positive results
that AT can improve the cognitive, psychological, and
behavioral domains of its participants, may provide a
new understanding and/or direction for further research
about the complex relationships between a motivation-
enhancing and insight-inducing psychosocial intervention
and the above psychosocial and behavioral variables, as
well as side effects of medications used and patients’
symptom severity [38].
The AT used in this trial was conducted by six trained
community psychiatric nurses. In contrast with recent
interventional studies in which there were limited mea-
sures in monitoring the treatment fidelity, the AT was
guided by a validated manual and delivered by these six
nurse therapists with adequate training and supervised
practice before conducting the intervention. In addition,
a high level of competency in their implementation of
the intervention (the median rating on the trained
nurses’ competency by two independent assessors was
94 %) was demonstrated. Such a high level of treatment
fidelity can increase the treatment integrity, thus enhan-
cing the internal validity of the study [16,27] and the
completion rate of this AT program.
This approach to AT showed very clear benefits in
terms of psychopathology and treatment insight and
adherence for patients with acute to three-year duration of
schizophrenia, who indicated poor medication adherence
Chien et al. Trials  (2015) 16:270 Page 12 of 14and moderate psychotic symptoms and functioning.
The sample recruited could represent those patients
with the particular need for an effective medication and
illness management during the early stages of psychotic
disorders; importantly, it was in contrast to recent AT
studies in which most participants were in low to mod-
erate levels of non-adherence to medication [9,13,16].
The participants’ non-adherence rate (76 to 79 %) at base-
line measurement in this trial were comparable with most
epidemiological and clinical studies for early stages of
psychosis [25,39], thus enhancing the generalizability of
these findings to current clinical and patient situations.
Recent reviews have suggested that the effects of AT
could not be considered substantive in a medium term
(six months) follow-up period; similar AT programs with
a course of four to six sessions were unable to show
significant effects on important patient outcomes, such
as positive and negative symptoms and even relapse rate
[5,36]. Nevertheless, the results of this controlled trial
can confirm the medium-term effect of AT on most of
the outcome measures, with an observable reduced
frequency of re-hospitalizations over the six-month
follow-up period. Previous research has suggested that
the effects of AT based on the motivational interviewing
technique appeared to be modest and inconclusive
[8,12,40]; however, the findings of this trial support and
reinforce the importance of such approach and show
that it can be effective in improving the psychosocial
health outcomes of people in the early stage (less than
five years) of schizophrenia spectrum disorders. The
findings also echoed the recommendations by Gray
et al. [16]: that adherence modifying factors essentially
centered on improved self-determination, patient choice,
and shared decision-making.
Furthermore, AT can embody the advantages of continu-
ous boosting of a patient’s intrinsic motivation, and reflect-
ing and managing barriers to medication (treatments) on
top of psychosocial support and psycho-pharmacological
education. This motivational-interviewing-based AT can
acknowledge the importance of patients’ involvement in
treatment decision and their understanding of both the
desirable and negative effects of antipsychotic medication,
as well as the possible consequences of adherence or
non-adherence to medication, such as unstable mental
condition, disturbing and challenging behaviors, and
higher risk of relapse [22]. Hence, this insight-inducing
and motivation-enhancing approach allows these pa-
tients to change their attitude toward medication use,
and determine their adherence to medication (treat-
ment) with fully informed, voluntary, and free choices.
Limitations and future study
A few limitations of this study should be noted. First,
while the refusal rate in this study was very low (7 %), over50 % of the patients in the outpatient clinic were found
not to be eligible to participate in this study. In addition,
the patients who volunteered to participate were mainly
full- or part-time employed (about 60 %), had a relatively
shorter duration of illness (64 to 66 % were in their first
year of illness), and had satisfactory family support (over
64 % living with family); consequently, they might be
highly motivated to participate in AT (indicated by the
high attendance rate). The patterns of sociodemographic
and illness characteristics, as well as their motivation to
change, might also not be representative of Hong Kong
and/or other Chinese populations with schizophrenia. Fu-
ture research with patients with diverse sociodemographic
and illness characteristics and/or adherence behaviors,
over a longer term follow-up (for example, 12 to
24 months), may allow investigation of the relationships
between the perceived benefits, levels of medication ad-
herence (as a mediator), and motivational interviewing
techniques, as well as the therapeutic mechanisms of the
intervention via individual and/or group interviews and/or
structured observations [19].
Second, although we found no difference between the
two study groups in terms of the types and dosage of
medication taken, we did not record data about side ef-
fects, changes in medications and their dosage, and
utilization of other mental health services; some of
which might have influenced patients’ mental condition
and/or insight into their illness and/or treatment. Further
research on the confounding effects of these medication-
and service-related variables on the effectiveness of AT for
people with schizophrenia is recommended.
Third, all of the outcome measures were reported by the
participants, except the level of adherence rated by the RA
and community psychiatric nurses. Future trials can con-
sider using biological assays such as hair and urine or
blood specimens, which are considered more objective
and reliable measurements in previous studies [14,25,34],
to validate or confirm with the non-invasive, self-reported
measures used in this study. Finally, the participants and
nurse therapists in this study were not blind to the AT and
TAU condition. There was also a lack of control for the
frequency and hours of home visits by the community
psychiatric nurses in the two study groups, and the work-
ing experiences of the nurse therapists in the CPNS. Pa-
tients’ preconceived benefits of the AT and the Hawthorne
effect due to their awareness of the interventions received
might have affected the participants’ (and nurse thera-
pists’) perceived benefits, the participants’ efforts and/or
responses and enthusiasm to the interventions, and thus
their reported outcomes.
Conclusions
This controlled trial has been successful in utilizing the
strengths of motivational interviewing-based AT for people
Chien et al. Trials  (2015) 16:270 Page 13 of 14with schizophrenia spectrum disorders to improve a variety
of patient outcomes, including not only patients’ symptom
severity and medication adherence, but also their function-
ing, insight to illness and/or treatment, and number of re-
hospitalizations, over a six-month follow-up period. The
findings provide evidence on the positive effects of this AT
program for schizophrenia sufferers who present with mild
to moderate psychotic (both positive and negative) symp-
toms and poor adherence to medication regimens in
psychiatric outpatient clinics. AT, which is a structured and
self-empowering model of psychosocial intervention
used in conjunction with psycho-pharmacological and
other psychiatric treatments, has explicit benefits and
applicability to Chinese patients with schizophrenia
and other psychotic disorders, and deserves further re-
search into its suitability for a wider implementation in
community-based rehabilitation for diverse psychiatric
patient groups, and across cultures.
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